Abstract
The objective of this manuscript is to provide a comprehensive review of the relation between adiposity and Alzheimers disease (AD), its potential mechanisms, and issues in its study. Adiposity represents the body fat tissue content. When the degree of adiposity increases it can be defined as being overweight or obese by measures such as the body mass index. Being overweight or obese is a cause of hyperinsulinemia and diabetes, both of which are risk factors for AD. However, the epidemiologic evidence linking the degree of adiposity and AD is conflicting. Traditional adiposity measures such as body mass index have decreased validity in the elderly. Increased adiposity in early or middle adult life leads to hyperinsulinemia which may lead to diabetes later in life. Thus, the timing of ascertainment of adiposity and its related factors is critical in understanding how it might fit into the pathogenesis of AD. We believe that the most plausible mechanism relating adiposity to AD is hyperinsulinemia, but it is unclear whether specific products of adipose tissue also have a role. Being overweight or obese is increasing in children and adults, thus understanding the association between adiposity and AD has important public health implications.
Keywords: body mass index, hyperinsulinemia, glucose intolerance, Adipokines, Advanced Products of Glycosilation (AGE)
Current Alzheimer Research
Title: Adiposity and Alzheimers Disease
Volume: 4 Issue: 2
Author(s): Jose A. Luchsinger and Richard Mayeux
Affiliation:
Keywords: body mass index, hyperinsulinemia, glucose intolerance, Adipokines, Advanced Products of Glycosilation (AGE)
Abstract: The objective of this manuscript is to provide a comprehensive review of the relation between adiposity and Alzheimers disease (AD), its potential mechanisms, and issues in its study. Adiposity represents the body fat tissue content. When the degree of adiposity increases it can be defined as being overweight or obese by measures such as the body mass index. Being overweight or obese is a cause of hyperinsulinemia and diabetes, both of which are risk factors for AD. However, the epidemiologic evidence linking the degree of adiposity and AD is conflicting. Traditional adiposity measures such as body mass index have decreased validity in the elderly. Increased adiposity in early or middle adult life leads to hyperinsulinemia which may lead to diabetes later in life. Thus, the timing of ascertainment of adiposity and its related factors is critical in understanding how it might fit into the pathogenesis of AD. We believe that the most plausible mechanism relating adiposity to AD is hyperinsulinemia, but it is unclear whether specific products of adipose tissue also have a role. Being overweight or obese is increasing in children and adults, thus understanding the association between adiposity and AD has important public health implications.
Export Options
About this article
Cite this article as:
Luchsinger A. Jose and Mayeux Richard, Adiposity and Alzheimers Disease, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362100
DOI https://dx.doi.org/10.2174/156720507780362100 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs)
Recent Patents on Cardiovascular Drug Discovery The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Walnut Extract Inhibits the Fibrillization of Amyloid Beta-Protein, and also Defibrillizes its Preformed Fibrils
Current Alzheimer Research Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one
Letters in Drug Design & Discovery